SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells

Shi, Dazun; Zhang, Yu; Tian, Yan

doi:10.2147/cmar.s278012

Cited by 10 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that ROS can activate both autophagy and apoptosis. In contrast to apoptosis, autophagy can promote the progression of cancer cells [332]. Therefore, if autophagy activation occurs following pharmacological intervention and enhancing ROS levels in CP chemotherapy, the exact role of autophagy should be determined, and if autophagy functions as a pro-survival mechanism, autophagy inhibitors, such as chloroquine can be utilized.…”

Section: Conclusion and Remarksmentioning

confidence: 99%

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

et al. 2021

View full text Add to dashboard Cite

The failure of chemotherapy is a major challenge nowadays, and in order to ensure effective treatment of cancer patients, it is of great importance to reveal the molecular pathways and mechanisms involved in chemoresistance. Cisplatin (CP) is a platinum-containing drug with anti-tumor activity against different cancers in both pre-clinical and clinical studies. However, drug resistance has restricted its potential in the treatment of cancer patients. CP can promote levels of free radicals, particularly reactive oxygen species (ROS) to induce cell death. Due to the double-edged sword role of ROS in cancer as a pro-survival or pro-death mechanism, ROS can result in CP resistance. In the present review, association of ROS with CP sensitivity/resistance is discussed, and in particular, how molecular pathways, both upstream and downstream targets, can affect the response of cancer cells to CP chemotherapy. Furthermore, anti-tumor compounds, such as curcumin, emodin, chloroquine that regulate ROS and related molecular pathways in increasing CP sensitivity are described. Nanoparticles can provide co-delivery of CP with anti-tumor agents and by mediating photodynamic therapy, and induce ROS overgeneration to trigger CP sensitivity. Genetic tools, such as small interfering RNA (siRNA) can down-regulate molecular pathways such as HIF-1α and Nrf2 to promote ROS levels, leading to CP sensitivity. Considering the relationship between ROS and CP chemotherapy, and translating these findings to clinic can pave the way for effective treatment of cancer patients.

show abstract

Section: Conclusion and Remarksmentioning

confidence: 99%

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

et al. 2021

View full text Add to dashboard Cite

show abstract

“…LAT2 promotes the progression of multiple tumors and drug resistance (47,48). SLAMF1 promotes methotrexate resistance by activating autophagy of choriocarcinoma cells (49). Moreover, it serves as a prognostic marker gene of chronic lymphoblastic leukemia (CLL) (50,51).…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort

Zhang

2022

Front. Med.

View full text Add to dashboard Cite

BackgroundThe incidence and mortality rates of colon adenocarcinoma (COAD), which is the fourth most diagnosed cancer worldwide, are high. A subset of patients with COAD has shown promising responses to immunotherapy. However, the percentage of patients with COAD benefiting from immunotherapy is unclear. Therefore, gaining a better understanding of the immune milieu of colon cancer could aid in the development of immunotherapy and suitable combination strategies.MethodsIn this study, gene expression profiles and clinical follow-up data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and molecular subtypes were identified using the ConsensusClusterPlus package in R. Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic value of immune subtypes. The graph structure learning method was used to reduce the dimension to reveal the internal structure of the immune system. Weighted correlation network analysis (WGCNA) was performed to identify immune-related gene modules. Finally, western blotting was performed to verify the gene expression patterns in COAD samples.ResultsThe results showed that 424 COAD samples could be divided into three subtypes based on 1921 immune cell-related genes, with significant differences in prognosis between subtypes. Furthermore, immune-related genes could be divided into five functional modules, each with a different distribution pattern of immune subtypes. Immune subtypes and gene modules were highly reproducible across many data sets. There were significant differences in the distribution of immune checkpoints, molecular markers, and immune characteristics among immune subtypes. Four core genes, namely, CD2, FGL2, LAT2, and SLAMF1, with prognostic significance were identified by WGCNA and univariate Cox analysis.ConclusionOverall, this study provides a conceptual framework for understanding the tumor immune microenvironment of colon cancer.

show abstract

“…Correctly assessing and predicting GTN chemoresistance, exploring the relevant molecular mechanisms of chemoresistance, and searching for chemoresistance predictors and potential therapeutic targets are urgent clinical needs. Previous studies have confirmed that MTX resistance is related to a variety of molecules, such as ABC transporter and multidrug resistance-related protein (MRP1) pumping out drugs, resulting in a decrease in intracellular drug concentrations ( 11 ). Dipeptidyl peptidase-4 (DPP4), methyltransferase-like protein 7A (METTL7A), and transcription factor SOX8 may promote MTX resistance by activating pro-survival signaling pathways and reducing the accumulation of reactive oxygen species (ROS) in JEG3 cells ( 12 ).…”

Section: Discussionmentioning

confidence: 99%

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Zhang²,

Yin³

2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo investigate the monotherapy for gestational trophoblastic neoplasia (GTN) patients with FIGO/WHO prognostic score of 5–6.MethodsThe low-risk GTN patients from 2012 to 2019 were enrolled. The study is a retrospective report to analyze the efficacy and safety of single-agent chemotherapy and combination chemotherapy in patients with a high FIGO/WHO prognostic score of 5–6.Results75 cases (33.5%) were included. Complete remission was in all patients. Among the 29 cases taking single-agent chemotherapy, 22 cases (75.9%) developed drug resistance. Among the 46 cases taking combination chemotherapy, 7 patients (15.2%) developed drug resistance. There was a statistically significant difference in the drug resistance rate between these two subgroups (P < 0.05), but there was not statistically significant difference in the total number of chemotherapy courses (<2mIU/ml) (P < 0.05).ConclusionMonotherapy showed remarkable advantages in GTN patients with FIGO/WHO prognostic score of 5–6.

show abstract

SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells

Cited by 10 publications

References 35 publications

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies

Identification and Validation of Immune Molecular Subtypes and Immune Landscape Based on Colon Cancer Cohort

Monotherapy for low-risk gestational trophoblastic neoplasia with score 5-6

Contact Info

Product

Resources

About